Labcorp Holdings Inc. $LH Stake Lowered by Curated Wealth Partners LLC

Posted by Francis Steltz on Oct 17th, 2026

Curated Wealth Partners LLC cut its holdings in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 98.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,423 shares of the medical research company’s stock after selling 118,118 shares during the quarter. Curated Wealth Partners LLC’s holdings in Labcorp were worth $438,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in LH. Mather Group LLC. increased its position in Labcorp by 8.5% in the 3rd quarter. Mather Group LLC. now owns 1,292 shares of the medical research company’s stock valued at $398,000 after acquiring an additional 101 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Labcorp during the third quarter worth approximately $239,000. Krilogy Financial LLC lifted its position in shares of Labcorp by 2.4% during the third quarter. Krilogy Financial LLC now owns 1,590 shares of the medical research company’s stock worth $502,000 after purchasing an additional 37 shares in the last quarter. NorthCrest Asset Manangement LLC lifted its position in shares of Labcorp by 1.6% during the third quarter. NorthCrest Asset Manangement LLC now owns 32,086 shares of the medical research company’s stock worth $10,082,000 after purchasing an additional 495 shares in the last quarter. Finally, Lawood & Co. grew its stake in shares of Labcorp by 8.2% during the third quarter. Lawood & Co. now owns 991 shares of the medical research company’s stock valued at $305,000 after purchasing an additional 75 shares during the last quarter. 95.94% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Weiss Ratings raised shares of Labcorp from a “buy (b)” rating to a “buy (b+)” rating in a report on Tuesday, October 6th. Morgan Stanley boosted their price objective on shares of Labcorp from $308.00 to $338.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $306.00 price objective on shares of Labcorp in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. increased their price objective on Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Labcorp currently has an average rating of “Moderate Buy” and a consensus price target of $337.73.

Read Our Latest Stock Report on Labcorp

Labcorp Price Performance

LH opened at $318.44 on Friday. The company has a fifty day moving average price of $320.58 and a two-hundred day moving average price of $289.08. The firm has a market capitalization of $25.83 billion, a PE ratio of 18.59, a P/E/G ratio of 1.85 and a beta of 0.87. Labcorp Holdings Inc. has a 52 week low of $244.52 and a 52 week high of $341.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80.

Labcorp (NYSE:LH – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, beating analysts’ consensus estimates of $4.78 by $0.21. The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.35 EPS. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, analysts anticipate that Labcorp Holdings Inc. will post 18.32 earnings per share for the current year.

Insider Buying and Selling

In other Labcorp news, Director Kerrii B. Anderson sold 3,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $318.02, for a total value of $954,060.00. Following the transaction, the director owned 6,563 shares of the company’s stock, valued at approximately $2,087,165.26. This represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 4,669 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the transaction, the chief executive officer owned 102,565 shares in the company, valued at approximately $32,858,749.05. This trade represents a 4.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,593 shares of company stock valued at $2,733,295 over the last three months. Company insiders own 0.84% of the company’s stock.

Labcorp Profile

(Free Report)

Labcorp (NYSE:LH), formally Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing, drug development services and technology-enabled laboratory solutions to healthcare providers, pharmaceutical and biotechnology companies, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including testing related to oncology, women’s health, infectious diseases, genetics and genomics.